866-997-4948(US-Canada Toll Free)

Antiviral Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2016 - 2024

Published By :

Transparency

Published Date : Mar 2017

Category :

Pharmaceutical

No. of Pages : 184 Pages

Global Antiviral Drugs Market: Overview

In past 30 years, significant progress is seen in antiviral drugs market, mainly in case of the drugs that target the entry and escaping mechanisms of viruses, with an aim of improving the quality of patients life by introducing broad spectrum of combination therapy drugs. Viruses rely on hosts machinery for replication as well as metabolic activities, thus antiviral agents target these mechanisms by several inhibitor classes such as Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Fusion Inhibitors (FIs), Entry Inhibitors - CCR5 co-receptor antagonist, Protease Inhibitors (PIs), HIV Integrase strand transfer inhibitors, among others.

Demand for new and improved targeted therapies for viral diseases continues to rise, primarily due to invention of broad spectrum antiviral drugs. Introduction of combinational drug therapies with improved pharmacokinetic and pharmacodynamics properties, and focus on emerging regions for market penetration by creating awareness along with availability of affordable drugs are major opportunities for the global antiviral drugs market.

The market overview section of the report comprises qualitative analysis of the overall antiviral drugs market considering the factors determining the market dynamics such as drivers, restraints and opportunities, along with Porters five force analysis and market attractiveness analysis. In addition, such as market opportunity analysis for the disease indications, product type, and distribution channels, and key industry developments has also been provided. Key industry developments include the major events occurred in past decade and are expected to occur during the forecast period which are likely to affect the market dynamics. The prevalence HIV infection and HCV infection has also been provided, along with the FDA approvals and patent expiries of major drugs by each drug class. The pipeline analysis of major market players has been given in the market overview section.

Global Antiviral Drugs Market: Segmentation

The global antiviral drugs market has been segmented on the basis of disease indication, product type, and distribution channels. On the basis of disease indication, the global antiviral drugs market is categorized as hepatitis virus infection, HIV infection, Respiratory virus infection, and others. In terms of product type, the global antiviral drugs market is divided into branded drugs, and generic drugs. Furthermore, on the basis of distribution channels, the global antiviral drugs market has been classified as hospital pharmacy store, retail pharmacy store, and online pharmacy.

The market for these disease indication, product type, and distribution channels has been extensively analyzed on the basis of factors such as drug usage pattern, sales revenue, geographic presence and technological developments. The market size and forecast in terms of revenue (USD million) for each of these segments have been provided for the period 2014 to 2024, considering 2015 as the base year. The report also provides the compounded annual growth rate (CAGR) for each segment for the forecast period 2016 to 2024.

Geographically, the antiviral drugs market has been classified into five segments, namely, North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The market size and forecast for each region has been provided for the period 2014 to 2024, in terms of disease indication, product type, and distribution channels, along with the CAGR (%) for the forecast period 2016 to 2024.

Global Antiviral Drugs Market: Competitive Analysis

The report also provides a section on the competitive landscape, wherein the market share analysis of leading players in the global antiviral drugs market, in terms of percentage share in 2016 (estimated) has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the market and increase their market share.

The report concludes with the profiles of major players in the global antiviral drugs market such as AbbVie, Inc., Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., Mylan N.V., GlaxoSmithKline plc. Johnson & Johnson, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., among others. The major market players are evaluated on various parameters such as company overview, financial overview, product portfolio, business strategies and recent developments.

The global antiviral drugs market is segmented as follows:

By Disease Indication

  • Hepatitis Virus Infection
  • HIV Infection
  • Respiratory Virus Infection
  • Others

By Product Type

  • Branded Drugs
  • Generic Drugs

By Distribution Channels

  • Hospital Pharmacy Store
  • Retail Pharmacy Store
  • Online Pharmacy

By Geography

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Table of Content

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Antiviral Drugs Market

4. Market Overview
4.1. Introduction
4.1.1. Disease Indication Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Key Market Indicators
4.4. Market Dynamics
4.4.1. Drivers
4.4.2. Restraints
4.4.3. Opportunity
4.5. Global Antiviral Drugs Market Analysis and Forecasts, 20142024
4.5.1. Market Revenue Projections (US$ Mn)
4.6. Porters Five Force Analysis
4.7. Market Outlook
4.8. Antiviral Drugs: FDA Approvals and Patent Expiries by each drug class
4.9. Global relative prevalence rate of each hepatitis genotype infection
4.10. Global relative prevalence rate of HIV infection
4.11. Pipeline Analysis: Major Market Players

5. Global Antiviral Drugs Market Analysis and Forecasts, By Disease Indication
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Key Trends
5.4. Market Value Forecast by Disease Indication, 20142024
5.4.1. Hepatitis Virus Infection
5.4.2. HIV Infection
5.4.3. Respiratory Virus Infection
5.4.4. Others
5.5. Market Attractiveness by Disease Indication

6. Global Antiviral Drugs Market Analysis and Forecasts, by Product Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Key Trends
6.4. Market Value Forecast by Product Type, 20142024
6.4.1. Branded Drugs
6.4.2. Generic Drugs
6.5. Market Attractiveness by Product Type

7. Global Antiviral Drugs Market Analysis and Forecasts, by Distribution Channels
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Key Trends
7.4. Market Value Forecast by Distribution Channels, 20142024
7.4.1. Hospital Pharmacy Store
7.4.2. Retail Pharmacy Store
7.4.3. Online Pharmacy
7.5. Market Attractiveness by Distribution Channels

8. Global Antiviral Drugs Market Analysis and Forecasts, by Region
8.1. Key Findings
8.2. Policies and Regulations
8.3. Market Value Forecast by Region
8.3.1. North America
8.3.2. Europe
8.3.3. Asia Pacific
8.3.4. Latin America
8.3.5. Middle East and Africa
8.4. Market Attractiveness by Country/Region

9. North America Antiviral Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.1.2. Policies and Regulations
9.1.3. Key Trends
9.2. Market Value Forecast by Disease Indication, 20142024
9.2.1. Hepatitis Virus Infection
9.2.2. HIV Infection
9.2.3. Respiratory Virus Infection
9.2.4. Others
9.3. Market Value Forecast by Product Type, 20142024
9.3.1. Branded Drugs
9.3.2. Generic Drugs
9.4. Market Value Forecast by Distribution Channels, 20142024
9.4.1. Hospital Pharmacy Store
9.4.2. Retail Pharmacy Store
9.4.3. Online Pharmacy
9.5. Market Value Forecast by Country, 20142024
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Disease Indication
9.6.2. By Product Type
9.6.3. By Distribution Channels
9.6.4. By Country

10. Europe Antiviral Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.1.2. Policies and Regulations
10.1.3. Key Trends
10.2. Market Value Forecast by Disease Indication, 20142024
10.2.1. Hepatitis Virus Infection
10.2.2. HIV Infection
10.2.3. Respiratory Virus Infection
10.2.4. Others
10.3. Market Value Forecast by Product Type, 20142024
10.3.1. Branded Drugs
10.3.2. Generic Drugs
10.4. Market Value Forecast by Distribution Channels, 20142024
10.4.1. Hospital Pharmacy Store
10.4.2. Retail Pharmacy Store
10.4.3. Online Pharmacy
10.5. Market Value Forecast by Country, 20142024
10.5.1. U.K.
10.5.2. Germany
10.5.3. France
10.5.4. Italy
10.5.5. Spain
10.5.6. Russia
10.5.7. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. By Disease Indication
10.6.2. By Product Type
10.6.3. By Distribution Channels
10.6.4. By Country

11. Asia Pacific Antiviral Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.1.2. Policies and Regulations
11.1.3. Key Trends
11.2. Market Value Forecast by Disease Indication, 20142024
11.2.1. Hepatitis Virus Infection
11.2.2. HIV Infection
11.2.3. Respiratory Virus Infection
11.2.4. Others
11.3. Market Value Forecast by Product Type, 20142024
11.3.1. Branded Drugs
11.3.2. Generic Drugs
11.4. Market Value Forecast by Distribution Channels, 20142024
11.4.1. Hospital Pharmacy Store
11.4.2. Retail Pharmacy Store
11.4.3. Online Pharmacy
11.5. Market Value Forecast by Country, 20142024
11.5.1. India
11.5.2. China
11.5.3. Japan
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
11.6.1. By Disease Indication
11.6.2. By Product Type
11.6.3. By Distribution Channels
11.6.4. By Country

12. Latin America Antiviral Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.1.2. Policies and Regulations
12.1.3. Key Trends
12.2. Market Value Forecast by Disease Indication, 20142024
12.2.1. Hepatitis Virus Infection
12.2.2. HIV Infection
12.2.3. Respiratory Virus Infection
12.2.4. Others
12.3. Market Value Forecast by Product Type, 20142024
12.3.1. Branded Drugs
12.3.2. Generic Drugs
12.4. Market Value Forecast by Distribution Channels, 20142024
12.4.1. Hospital Pharmacy Store
12.4.2. Retail Pharmacy Store
12.4.3. Online Pharmacy
12.5. Market Value Forecast by Country, 20142024
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis
12.6.1. By Disease Indication
12.6.2. By Product Type
12.6.3. By Distribution Channels
12.6.4. By Country

13. Middle East and Africa Antiviral Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.1.2. Policies and Regulations
13.1.3. Key Trends
13.2. Market Value Forecast by Disease Indication, 20142024
13.2.1. Hepatitis Virus Infection
13.2.2. HIV Infection
13.2.3. Respiratory Virus Infection
13.2.4. Others
13.3. Market Value Forecast by Product Type, 20142024
13.3.1. Branded Drugs
13.3.2. Generic Drugs
13.4. Market Value Forecast by Distribution Channels, 20142024
13.4.1. Hospital Pharmacy Store
13.4.2. Retail Pharmacy Store
13.4.3. Online Pharmacy
13.5. Market Value Forecast by Country, 20142024
13.5.1. South Africa
13.5.2. GCC Countries
13.5.3. Rest of Middle East and Africa
13.6. Market Attractiveness Analysis
13.6.1. By Disease Indication
13.6.2. By Product Type
13.6.3. By Distribution Channels
13.6.4. By Country

14. Competition Landscape
14.1. Market Player Competition Matrix (By Tier and Size of companies)
14.2. Market Share Analysis by Company 2016 (Estimated)
14.3. Company Profiles (Details Overview, Financials, Recent Developments, Strategy)
14.3.1. AbbVie, Inc.
14.3.1.1 Company Overview (HQ, Business Segments, Employee Strengths)
14.3.1.2 Financial Overview
14.3.1.3 Product Portfolio
14.3.1.4 SWOT Analysis
14.3.1.5 Strategic Overview
14.3.2. Bristol-Myers Squibb Company
14.3.2.1 Company Overview (HQ, Business Segments, Employee Strengths)
14.3.2.2 Financial Overview
14.3.2.3 Product Portfolio
14.3.2.4 SWOT Analysis
14.3.2.5 Strategic Overview
14.3.3. Cipla, Inc.
14.3.3.1 Company Overview (HQ, Business Segments, Employee Strengths)
14.3.3.2 Financial Overview
14.3.3.3 Product Portfolio
14.3.3.4 SWOT Analysis
14.3.3.5 Strategic Overview
14.3.4. F. Hoffmann-La Roche Ltd.
14.3.4.1 Company Overview (HQ, Business Segments, Employee Strengths)
14.3.4.2 Financial Overview
14.3.4.3 Product Portfolio
14.3.4.4 SWOT Analysis
14.3.4.5 Strategic Overview
14.3.5. Gilead Sciences, Inc.
14.3.5.1 Company Overview (HQ, Business Segments, Employee Strengths)
14.3.5.2 Financial Overview
14.3.5.3 Product Portfolio
14.3.5.4 SWOT Analysis
14.3.5.5 Strategic Overview
14.3.6. GlaxoSmithKline plc.
14.3.6.1 Company Overview (HQ, Business Segments, Employee Strengths)
14.3.6.2 Financial Overview
14.3.6.3 Product Portfolio
14.3.6.4 SWOT Analysis
14.3.6.5 Strategic Overview
14.3.7. Johnson & Johnson
14.3.7.1 Company Overview (HQ, Business Segments, Employee Strengths)
14.3.7.2 Financial Overview
14.3.7.3 Product Portfolio
14.3.7.4 SWOT Analysis
14.3.7.5 Strategic Overview
14.3.8. Merck & Co., Inc.
14.3.8.1 Company Overview (HQ, Business Segments, Employee Strengths)
14.3.8.2 Financial Overview
14.3.8.3 Product Portfolio
14.3.8.4 SWOT Analysis
14.3.8.5 Strategic Overview
14.3.9. Mylan N.V.
14.3.9.1 Company Overview (HQ, Business Segments, Employee Strengths)
14.3.9.2 Financial Overview
14.3.9.3 Product Portfolio
14.3.9.4 SWOT Analysis
14.3.9.5 Strategic Overview
14.3.10. Teva Pharmaceutical Industries Ltd.
14.3.10.1 Company Overview (HQ, Business Segments, Employee Strengths)
14.3.10.2 Financial Overview
14.3.10.3 Product Portfolio
14.3.10.4 SWOT Analysis
14.3.10.5 Strategic Overview
14.3.11. Others

List of Table

Table 01: Global Antiviral Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 20142024
Table 02: Global Antiviral Drugs Market Size (US$ Mn) Forecast, by Product, 20142024
Table 03: Global Antiviral Drugs Market Size (US$ Mn) Forecast, by Distribution Channels, 20142024
Table 04: Global Antiviral Drugs Market Size (US$ Mn) Forecast, by Region, 20142024
Table 05: North America Antiviral Drugs Market Size (US$ Mn) Forecast, by Country, 20142024
Table 06: North America Antiviral Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 20142024
Table 07: North America Antiviral Drugs Market Size (US$ Mn) Forecast, by Product, 20142024
Table 08: North America Antiviral Drugs Market Size (US$ Mn) Forecast, by Distribution Channels, 20142024
Table 09: Europe Antiviral Drugs Market Size (US$ Mn) Forecast, by Country/Region, 20142024
Table 10: Europe Antiviral Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 20142024
Table 11: Europe Antiviral Drugs Market Size (US$ Mn) Forecast, by Product, 20142024
Table 12: Europe Antiviral Drugs Market Size (US$ Mn) Forecast, by Distribution Channels, 20142024
Table 13: Asia Pacific Antiviral Drugs Market Size (US$ Mn) Forecast, by Country/ Region, 20142024
Table 14: Asia Pacific Antiviral Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 20142024
Table 15: Asia Pacific Antiviral Drugs Market Size (US$ Mn) Forecast, by Product, 20142024
Table 16: Asia Pacific Antiviral Drugs Market Size (US$ Mn) Forecast, by Distribution Channels, 20142024
Table 17: Latin America Antiviral Drugs Market Size (US$ Mn) Forecast, by Country/Region, 20142024
Table 18: Latin America Antiviral Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 20142024
Table 19: Latin America Antiviral Drugs Market Size (US$ Mn) Forecast, by Product, 20142024
Table 20: Latin America Antiviral Drugs Market Size (US$ Mn) Forecast, by Distribution Channels, 20142024
Table 21: MEA Antiviral Drugs Market Size (US$ Mn) Forecast, by Country/ Region, 20142024
Table 22: Middle East & Africa Antiviral Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 20142024
Table 23: Middle East & Africa Antiviral Drugs Market Size (US$ Mn) Forecast, by Product, 20142024
Table 24: Middle East & Africa Antiviral Drugs Market Size (US$ Mn) Forecast, by Distribution Channels, 20142024

List of Chart


Figure 01: Global Antiviral Drugs Market Size (US$ Mn) Forecast, 20142024
Figure 02: FDA Approvals
Figure 03: FDA Approvals
Figure 04: FDA Approvals
Figure 05: FDA Approvals
Figure 06: FDA Approvals
Figure 07: FDA Approvals
Figure 08: FDA Approvals
Figure 09: FDA Approvals
Figure 10: HIV Prevalence
Figure 11: Hepatitis c virus prevalence
Figure 12: Pipeline Analysis
Figure 13: Global Antiviral Drugs Market Value Share Analysis, Disease Indication, 2016 and 2024
Figure 14: Global Hepatitis Virus Infection Antiviral Drugs Market Revenue (US$ Mn), 20142024
Figure 15: Global HIV Infection Antiviral Drugs Market Revenue (US$ Mn), 20142024
Figure 16: Global Respiratory Virus Infection Antiviral Drugs Market Revenue (US$ Mn), 20142024
Figure 17: Global Other Antiviral Drugs Market Revenue (US$ Mn), 20142024
Figure 18: Antiviral Drugs Market Attractiveness Analysis, Disease Indication, 20162024
Figure 19: Global Antiviral Drugs Market Value Share Analysis, by Product, 2016 and 2024
Figure 20: Global Branded Antiviral Drugs Market Revenue (US$ Mn), 20142024
Figure 21: Global Generic Antiviral Drugs Market Revenue (US$ Mn), 20142024
Figure 22: Antiviral Drugs Market Attractiveness Analysis, by Product, 20162024
Figure 23: Global Antiviral Drugs Market Value Share Analysis, by distribution Channels, 2016 and 2024
Figure 24: Global Hospital Pharmacy Store Antiviral Drugs Market Revenue (US$ Mn), 20142024
Figure 25: Global Retail Pharmacy Store Antiviral Drugs Market Revenue (US$ Mn), 20142024
Figure 26: Global Online Pharmacy Antiviral Drugs Market Revenue (US$ Mn), 20142024
Figure 27: Antiviral Drugs Market Attractiveness Analysis, by Distribution Channels, 20162024
Figure 28: Global Antiviral Drugs Market Value Share Analysis, by Region, 2016 and 2024
Figure 29: Antiviral Drugs Market Attractiveness Analysis, by Region, 20162024
Figure 30: North America Antiviral Drugs Market Size (US$ Mn) Forecast, 20142024
Figure 31: North America Market Attractiveness Analysis, by Country, 20162024
Figure 32: North America Market Value Share Analysis, by Country, 2016 and 2024
Figure 33: North America Antiviral Drugs Market Value Share Analysis, Disease Indication, 2016 and 2024
Figure 34: North America Antiviral Drugs Market Value Share Analysis, by Product, 2016 and 2024
Figure 35: North America Antiviral Drugs Market Value Share Analysis, by distribution Channels, 2016 and 2024
Figure 36: North America Market Attractiveness Analysis, by Disease Indication, 2016-2024
Figure 37: North America Market Attractiveness Analysis, by Product, 2016-2024
Figure 38: North America Market Attractiveness Analysis, by Distribution Channels, 2016-2024
Figure 39: Europe Antiviral Drugs Market Size (US$ Mn) Forecast, 20142024
Figure 40: Europe Market Attractiveness Analysis, by Country/ Region, 20162024
Figure 41: Europe Market Value Share Analysis, by Country/Region, 2016 and 2024
Figure 42: Europe Antiviral Drugs Market Value Share Analysis, Disease Indication, 2016 and 2024
Figure 43: Europe Antiviral Drugs Market Value Share Analysis, by Product, 2016 and 2024
Figure 44: Europe Antiviral Drugs Market Value Share Analysis, by distribution Channels, 2016 and 2024
Figure 45: Europe Market Attractiveness Analysis, by Disease Indication, 2016-2024
Figure 46: Europe Market Attractiveness Analysis, by Product, 2016-2024
Figure 47: Europe Market Attractiveness Analysis, by Distribution Channels, 2016-2024
Figure 48: Asia Pacific Antiviral Drugs Market Size (US$ Mn) Forecast, 20142024
Figure 49: Asia Pacific Market Attractiveness Analysis, by Country/Region, 20162024
Figure 50: Asia Pacific Market Value Share Analysis, by Country/ Region, 2016 and 2024
Figure 51: Asia Pacific Antiviral Drugs Market Value Share Analysis, Disease Indication, 2016 and 2024
Figure 52: Asia Pacific Antiviral Drugs Market Value Share Analysis, by Product, 2016 and 2024
Figure 53: Asia Pacific Antiviral Drugs Market Value Share Analysis, by distribution Channels, 2016 and 2024
Figure 54: Asia Pacific Market Attractiveness Analysis, by Disease Indication, 2016-2024
Figure 55: Asia Pacific Market Attractiveness Analysis, by Product, 2016-2024
Figure 56: Asia Pacific Market Attractiveness Analysis, by Distribution Channels, 2016-2024
Figure 57: Latin America Antiviral Drugs Market Size (US$ Mn) Forecast, 20142024
Figure 58: Latin America Market Attractiveness Analysis, by Country/Region, 20162024
Figure 59: Latin America Antiviral Drugs Market Value Share Analysis, by Country/Region, 2016 and 2024
Figure 60: Latin America Antiviral Drugs Market Value Share Analysis, Disease Indication, 2016 and 2024
Figure 61: Latin America Antiviral Drugs Market Value Share Analysis, by Product, 2016 and 2024
Figure 62: Latin America Antiviral Drugs Market Value Share Analysis, by distribution Channels, 2016 and 2024
Figure 63: Latin America Market Attractiveness Analysis, by Disease Indication, 2016-2024
Figure 64: Latin America Market Attractiveness Analysis, by Product, 2016-2024
Figure 65: Latin America Market Attractiveness Analysis, by Distribution Channels, 2016-2024
Figure 66: MEA Antiviral Drugs Market Size (US$ Mn) Forecast, 20142024
Figure 67: MEA Market Attractiveness Analysis, by Country/ Region, 2016-2024
Figure 68: MEA Antiviral Drugs Market Value Share Analysis, by Country/Region, 2016 and 2024
Figure 69: Middle East & Africa Antiviral Drugs Market Value Share Analysis, Disease Indication, 2016 and 2024
Figure 70: Middle East & Africa Antiviral Drugs Market Value Share Analysis, by Product, 2016 and 2024
Figure 71: Middle East & Africa Antiviral Drugs Market Value Share Analysis, by distribution Channels, 2016 and 2024
Figure 72: Middle East & Africa Market Attractiveness Analysis, by Disease Indication, 2016-2024
Figure 73: Middle East & Africa Market Attractiveness Analysis, by Product, 2016-2024
Figure 74: Middle East & Africa Market Attractiveness Analysis, by Distribution Channels, 2016-2024
Figure 75: Global Antiviral Drugs Market Share Analysis, by Company, (2015)

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *